[go: up one dir, main page]

AU2001273413A1 - Method for treating cancer using an interleukin- 4 antagonist - Google Patents

Method for treating cancer using an interleukin- 4 antagonist

Info

Publication number
AU2001273413A1
AU2001273413A1 AU2001273413A AU7341301A AU2001273413A1 AU 2001273413 A1 AU2001273413 A1 AU 2001273413A1 AU 2001273413 A AU2001273413 A AU 2001273413A AU 7341301 A AU7341301 A AU 7341301A AU 2001273413 A1 AU2001273413 A1 AU 2001273413A1
Authority
AU
Australia
Prior art keywords
interleukin
antagonist
treating cancer
cancer
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001273413A
Inventor
Carl J. March
Larry F. O'neal
John D. Pluenneke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of AU2001273413A1 publication Critical patent/AU2001273413A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2001273413A 2000-07-12 2001-07-11 Method for treating cancer using an interleukin- 4 antagonist Abandoned AU2001273413A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21788800P 2000-07-12 2000-07-12
US60/217,888 2000-07-12
PCT/US2001/022015 WO2002004009A2 (en) 2000-07-12 2001-07-11 Method for treating cancer using an interleukin- 4 antagonist

Publications (1)

Publication Number Publication Date
AU2001273413A1 true AU2001273413A1 (en) 2002-01-21

Family

ID=22812896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001273413A Abandoned AU2001273413A1 (en) 2000-07-12 2001-07-11 Method for treating cancer using an interleukin- 4 antagonist

Country Status (3)

Country Link
US (1) US20020076409A1 (en)
AU (1) AU2001273413A1 (en)
WO (1) WO2002004009A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02011682A (en) 2000-05-26 2003-05-14 Immunex Corp Use of interleukin-4 antagonists and compositions thereof.
DE60232895D1 (en) * 2001-10-09 2009-08-20 Mayo Foundation USE OF AGONISTIC 4-1BB ANTIBODIES TO IMPROVE THE IMMUNE RESPONSE
US6811780B2 (en) 2002-05-01 2004-11-02 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
EP1444989A1 (en) * 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
US20060018829A1 (en) * 2004-07-22 2006-01-26 Smith Henry J Cellular receptors utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment
CA2625446A1 (en) * 2005-10-13 2007-04-19 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Means and methods for the prediction of joint destruction
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
WO2007107349A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treament of cancer
BRPI0713484A2 (en) * 2006-06-21 2012-11-06 Apogenix Gmbh cytokine differential expression in human cancer
AU2007271349A1 (en) * 2006-07-06 2008-01-10 Apogenix Gmbh Human IL-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2591804A3 (en) * 2007-09-24 2014-04-16 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
AU2009231482A1 (en) * 2008-04-02 2009-10-08 Apogenix Gmbh Binding agents directed against IL-4 receptor for the treatment of tumors, inflammatory and immunological disorders
EP2596802A1 (en) 2011-11-23 2013-05-29 PLS-Design GmbH Pharmaceutical composition for treatment of allergic reactions
TWI573792B (en) 2012-02-01 2017-03-11 歐陸斯迪公司 Novel therapeutic agent
EP2674168A1 (en) 2012-06-14 2013-12-18 PLS-Design GmbH Modulation of effector T cell responses by local depletion of complement component C3
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (en) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedures for the treatment of cancer in patients with elevated levels of Bim
WO2015179654A1 (en) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti b7-h1 antibodies
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
US10875923B2 (en) 2015-10-30 2020-12-29 Mayo Foundation For Medical Education And Research Antibodies to B7-H1
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research CANCER TREATMENT METHODS AND MATERIALS
EP3897626B1 (en) 2018-12-18 2025-09-10 Mundipharma International Corporation Limited Tinostamustine for treating multiple myeloma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU643427B2 (en) * 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
DE69026627T2 (en) * 1989-12-20 1996-08-22 Schering Corp., Kenilworth, N.J. ANTIBODY ANTAGONISTS AGAINST HUMANES INTERLEUKIN-4
GB9124347D0 (en) * 1991-11-15 1992-01-08 Isis Innovation Treatment of macrophages

Also Published As

Publication number Publication date
WO2002004009A3 (en) 2003-08-21
US20020076409A1 (en) 2002-06-20
WO2002004009A2 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
AU2001273413A1 (en) Method for treating cancer using an interleukin- 4 antagonist
AU2001227966A1 (en) Methods for treating tumors
AU2651701A (en) Method for introducing additives
AU2001238126A1 (en) Apparatus for local radiation therapy
AU2002350109A1 (en) Methods and apparatus for cryo-therapy
AU2001238369A1 (en) Method for treating thyroid disorders
AU2001264771A1 (en) Well reference apparatus and method
AU2002218140A1 (en) Beam-shaping method
AU2001255602A1 (en) Methods for treating bone tumors
AU2003287210A1 (en) Method for treating emissions
AU2001249980A1 (en) Apparatus for local radiation therapy
AU2001276032A1 (en) Method and apparatus for enhancing an applause
AU2001262978A1 (en) Method and apparatus for interference reduction
AU2002360593A1 (en) Method and apparatus for nano-sensing
AU2002308642A1 (en) Methods for treating cancer
AU2001277938A1 (en) Method for treating angina
HK1043935A1 (en) Method for treating copd
AU2001236783A1 (en) Apparatus for local radiation therapy
AU2001253836A1 (en) Method of treating cancer
AU5867901A (en) Method for detecting tumors
AU2001295036A1 (en) Apparatus for performing microcurrentelectrotherapy
GB0118883D0 (en) Method for treating objects
GB0123898D0 (en) Method for treating objects
GB0123897D0 (en) Method for treating objects
GB0122810D0 (en) Method for treating objects